Additionally, the report, published by Apollo Healthcare, shows that close to 70 per cent of young adults are deficient in vitamin D, a crucial micronutrient essential for maintaining bone health and supporting immune functions. Such deficiencies are increasingly coming to light amidst a broader discussion on public health in India.

The findings stem from an analysis of over three million preventive health assessments conducted within the Apollo Healthcare system in 2025. The report underscores the growing prevalence of health deficiencies and the increasing incidence of prediabetes, along with the identification of many undetected health conditions affecting individuals.

Assessment of Overall Health and Risk Factors

Further insights from the report reveal that nearly two-thirds of individuals under the age of thirty exhibit poor flexibility, strength, or balance. These physical limitations are linked to increased risks of cardiovascular issues, falls, and potentially reduced life expectancy. Such results call for urgent public health interventions to address these deficiencies.

The health burden is notably widespread, affecting both the student population and working professionals. Among a sample group of 20,164 college students aged between 17 and 25, approximately two in three were found to have at least one significant underlying health risk that required attention. This suggests that health issues are prevalent during youth, pointing to the necessity of raising awareness and implementing preventive strategies.

According to the report, around fifty per cent of working-class individuals, particularly those in their late 30s, are either prediabetic or diabetic, with eighty per cent classified as overweight. These numbers raise serious concerns regarding lifestyle choices and the urgent need for targeted health initiatives.

Importance of Individualised Health Care

Dr Prathap C. Reddy, Founder Chairman of Apollo Hospitals, emphasised the need for personalised approaches in healthcare. He stated that individualised prevention strategies are essential, as the risks associated with health vary greatly among individuals based on age, gender, and lifestyle choices.

The report also sheds light on women’s health, revealing that out of a sample of 350 women over the age of 40, one reported breast cancer, with all cases being asymptomatic. The analysis indicates that specific health patterns such as anaemia and rising obesity are prevalent in women as they age. Dr Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals, has called for prioritising breast cancer screenings, highlighting the importance of recognising the health burdens faced by women in India.

The report concludes by stating that continuous care and follow-up play a significant role in improving health outcomes, particularly for those with chronic conditions like high blood pressure and diabetes. While routine health checks can identify issues, it is the subsequent actions taken that contribute to effective management and better health.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post 20% Young Indians Prediabetic, 70% Vitamin D Deficient: Experts Warn of Rising Risk appeared first on The CSR Journal.

स्वास्थ्य पर जोर

प्रियंका चोपड़ा ने बताया कि डायबिटीज एक ऐसी बीमारी है जो समय पर उपचार और देखभाल से नियंत्रण में आ सकती है। उन्होंने सुझाव दिया कि लोग समय-समय पर अपनी जांच कराते रहें, ताकि किसी भी समस्या का पता समय पर लग सके। यह उनकी व्यक्तिगत अनुभवों पर आधारित है, जहां उन्होंने अपनी सेहत को प्राथमिकता दी।

बीमारी की पहचान जरूरी

प्रियंका ने कहा कि जब लोग डायबिटीज के लक्षणों से अनजान होते हैं, तो स्थिति और भी गंभीर हो सकती है। उन्होंने लोगों से अपील की कि वे अपनी सेहत की जांच नियमित रूप से कराएं और यदि आवश्यकता हो तो विशेषज्ञ से सलाह लें। इससे न केवल बीमारी की पहचान जल्दी होगी, बल्कि उसका इलाज भी प्रारंभ किया जा सकेगा।

भारतीय समाज पर प्रभाव

भारत में डायबिटीज के मामलों की संख्या तेजी से बढ़ रही है, और प्रियंका चोपड़ा जैसे सेलिब्रिटीज का जागरूकता अभियान इसमें महत्वपूर्ण हो सकता है। उनके बयान से लोगों में बीमारी के प्रति एक सकारात्मक दृष्टिकोन विकसित होगा। प्रियंका का मानना है कि समाज में इसके प्रति सही और सटीक जानकारी फैलाना जरूरी है।

जागरूकता अभियानों की आवश्यकता

प्रियंका ने जोर देकर कहा कि विभिन्न स्वास्थ्य अभियानों के जरिए लोगों को सही जानकारी प्रदान की जानी चाहिए। उनके अनुसार, इससे न केवल डायबिटीज बल्कि अन्य प्रमुख स्वास्थ्य मुद्दों पर भी ध्यान दिया जा सकता है। भारत में बढ़ती स्वास्थ्य समस्याओं के समाधान के लिए जागरूकता आवश्यक है।

प्रियंका की प्रेरणा

उनकी खुद की यात्रा ने उन्हें इस दिशा में काम करने के लिए प्रेरित किया है। प्रियंका का कहना है कि जब वे खुद डायबिटीज जैसी समस्या का सामना करती हैं, तो उन्होंने समझा कि इस बीमारी का सही तरीके से सामना कैसे किया जा सकता है। इससे न केवल वे बल्कि अन्य लोग भी प्रेरित हो सकते हैं।

भविष्य की योजनाएं

प्रियंका चोपड़ा ने भविष्य में इस जागरूकता को बढ़ाने के लिए कई कार्यक्रमों में भाग लेने की योजना बनाई है। उनका उद्देश्य है कि अधिक से अधिक लोग इस बीमारी के प्रति जागरूक हों और उपचार के रास्ते पर आगे बढ़ें। इससे ना केवल उनकी सेहत में सुधार होगा बल्कि वे अपने आसपास के लोगों को भी प्रेरित कर सकेंगे।

समाज में बदलाव ला सकते हैं सितारे

प्रियंका चोपड़ा का यह पहल सही दिशा में एक बड़ा कदम है। उनके अंदर इस समस्या को लेकर जागरूकता फैलाने की जिज्ञासा है। इससे अन्य हस्तियों और लोगों को भी इस दिशा में काम करने के लिए प्रेरणा मिलेगी और समाज में सही जानकारी पहुंचाने में मदद मिलेगी।

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post प्रियंका चोपड़ा का डायबिटीज जागरूकता पर जोर, बोलीं- “डायबिटीज से मत डरिए” appeared first on The CSR Journal.

Current Availability of Semaglutide in India

Currently, semaglutide is marketed in India under three key brands from Novo Nordisk: Rybelsus, an oral tablet; and the injectables Ozempic and Wegovy. Rybelsus became available in 2022, while Ozempic and Wegovy were introduced to the Indian market just last year. Their arrival coincided with the debut of Mounjaro by Eli Lilly, another GLP-1-based drug used for weight management and diabetes treatment, containing the active ingredient tirzepatide. Together, these medications have rapidly gained prominence in the field of metabolic medicine.

Mechanism and Popularity of GLP-1 Therapies

GLP-1 therapies function by imitating gut hormones that play critical roles in appetite regulation, insulin release, and digestion. By binding to receptors that influence pancreatic hormone output and gastrointestinal activity, these drugs effectively manage blood sugar levels while suppressing appetite. This dual function makes them increasingly favored for treating both type 2 diabetes and obesity, conditions that often coexist.

Domestic Manufacturers Prepare for Generic Release

The recent surge in interest for effective weight-loss treatments has drawn the attention of domestic manufacturers. Industry insiders indicate that over a dozen Indian pharmaceutical firms are gearing up to release generic semaglutide products once patent protection wanes. Initial entrants are expected to include companies such as Dr Reddy’s Laboratories, Sun Pharmaceutical Industries, and Zydus Lifesciences. The anticipated competition among these manufacturers is likely to dramatically decrease prices, with estimates suggesting a reduction of about 60 to 70 percent, making the treatment more affordable for Indian patients.

Current Pricing and Future Projections

At present, the cost of semaglutide remains high. A month’s supply of Rybelsus is priced between Rs 6,900 and Rs 9,000, while injectable Ozempic generally costs between Rs 8,800 and Rs 11,000 per month. Wegovy, which is primarily prescribed for weight management, ranges from Rs 11,850 to Rs 26,050 depending on dosage strength. The introduction of generic options may significantly lower these costs over time.

Wide Range of Generic Versions Under Development

Market analysts estimate that nearly 50 versions of generic semaglutide are currently in various stages of development within the pharmaceutical sector. As more manufacturers enter the market and production efforts expand, prices could potentially decrease by as much as 80 to 90 percent when compared to existing branded therapies. This expected decline in prices is likely to enhance accessibility in a country facing rising obesity and diabetes rates.

Anticipated Changes in Treatment Protocols

With the incoming wave of generic semaglutide, specialists believe that treatment protocols for obesity and diabetes in India might undergo significant revisions. According to endocrinologists, the broader availability of this medication could allow healthcare providers to consider GLP-1 therapies earlier in the treatment process, rather than limiting them to patients who have unsuccessfully tried multiple oral medications. The developments indicate a potential turning point in the management of these conditions.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post Countdown Begins for Generic Semaglutide Launch in India appeared first on The CSR Journal.

In a public notice released by DCGI’s Dr. Rajeev Raghuvanshi, it was highlighted that the products in question, being rDNA origin injectables, necessitate precise temperature control during storage, specifically between 2 to 8 degrees Celsius. These temperature conditions are crucial for maintaining the integrity of the formulations. Any deviation from these requirements could compromise the product’s quality and subsequently affect patient safety. The theft is currently under investigation by local law enforcement.

DCGI asks doctors to exercise caution in prescribing this insulin formulation

Following this advisory, the DCGI has called on doctors and healthcare professionals to exercise caution in prescribing this insulin formulation. The notice emphasized the importance of patient education regarding the reporting of any adverse drug reactions (ADRs). Patients are urged to obtain these products exclusively from authorized suppliers and always ensure they have proper invoices for their purchases.

The DCGI has also directed all state and union territory Drugs Controllers, as well as zonal and sub-zonal offices of the Central Drugs Standard Control Organization (CDSCO), to monitor the distribution of the aforementioned products rigorously. Authorities are expected to take requisite action as stipulate under the Drugs and Cosmetics Act of 1940, along with the relevant rules. This proactive measure aims to ensure that such incidents do not compromise public health and safety.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post DCGI Alerts on Stolen Insulin Batch in Odisha, Warns About Potential Risks appeared first on The CSR Journal.

Need for Localized Evidence

Health professionals have noted that therapies that are deemed effective in Western populations do not always yield the same health outcomes in Indian patients. Factors such as genetic diversity, dietary habits, climatic conditions, and varying patterns of disease contribute to the necessity for research tailored to Indian demographics. Dr. Ambuj Rao, a cardiologist affiliated with AIIMS Delhi, expressed the urgency for localized clinical research, referencing an ongoing influenza vaccine trial being conducted among heart patients at AIIMS. He emphasized that evidence from Western nations is inadequate given India’s unique flu cycles and public health challenges.

Implementation and Funding Details

Under this new initiative, networks composed of at least five hospitals will collaborate to assess various treatment approaches, medical procedures, digital healthcare tools, and lifestyle modifications within real-world scenarios unique to India. The primary goal is to identify therapeutic methods that are clinically effective as well as economically viable for the country’s government hospitals and public health initiatives. Each selected study will be eligible for government funding of up to Rs 8 crore over a four-year period, according to officials.

Unique Health Challenges in India

Dr. Ravinder Goswami from the endocrinology department at AIIMS Delhi highlighted that India’s tropical climate, the repeated cycles of socioeconomic stress, and unique dietary habits have led to specific metabolic and hormonal responses among Indian populations. These include characteristics such as insulin resistance, elevated cortisol levels, and altered body composition, which contribute to significant health issues like diabetes and hypertension. With consumption patterns increasingly leaning towards processed foods, there’s a pressing need for culturally relevant, India-specific treatment options that address these conditions.

Strengthening Research Capacity

In addition to refining treatment protocols, this initiative aims to enhance India’s research capabilities. Participating hospitals will undertake independent clinical trials, keep standardized digital records, and ensure transparent data sharing, which will minimize reliance on pharmaceutical-driven global studies. Public health experts are optimistic that this endeavor may considerably benefit patients, as even minor adjustments to treatment approaches grounded in Indian evidence could lead to improved health outcomes and potentially lower healthcare costs for families managing chronic conditions.

Future Implications for Healthcare

If this initiative proves successful, it could lead to a paradigm shift in how medical professionals prescribe treatments in India, ultimately ensuring that clinical decisions are informed by data sourced from Indian patients rather than assumptions extrapolated from international studies.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post ICMR Advocates for India-Specific Research on Lifestyle Diseases like Diabetes and Cancer appeared first on The CSR Journal.

Pointing out at the countries with high populations such as India, China, Pakistan, researchers from the International Diabetes Federation in Belgium, the India Diabetes Research Foundation and Dr A Ramachandran’s Diabetes Hospital in Chennai noted that the contribution of these countries to worldwide diabetes is much higher compared to other nations.

Will Pakistan surpass the United States by 2050?

In the 11^th edition of the International Diabetes Federation (IDF) Diabetes Atlas, there is an estimate of national, regional and global diabetes prevalence for 2024 and also a projection for 2050. In this Atlas there is an analysis of 215 countries and territories, for these 246 studies were conducted in between the years 2005 and 2024. In the study, it was noted that 589 million adults (over 11 per cent of the world’s adult population), aged 20-79, are living with metabolic disorder and some 13 per cent (853 million adults) would be affected by 2050, the study notes. Author of the study notes, “In 2024, one in nine adults worldwide was living with diabetes. The number of adults with diabetes in 2024 exceeded 500 million and is projected to rise to close to 900 million by 2050. Pakistan could surpass the US by 2050,”. Author also adds, “In 2024, the largest number of adults with diabetes aged 20-79 years was in China (148 million), followed by India (90 million), and the US (39 million),”.

Talking about the origin of the patients, the study noted that 4/5^th of the world’s diabetes population or 80.64 per cent were residing in low and middle-income countries in 2024. The research also noted that by 2050, these figures can increase upto 95 per cent. Stating the cause of the diabetes, the research noted that the population growth, population ageing, and ongoing urbanisation, have cumulatively contributed to the increase in cases.

Middle income countries have high prevalence of diabetes

What makes the data collection of diabetes even tougher is the resource-poor settings, and it is expected that there will be an increase in diabetes prevalence in these countries. As per the research 25 percent of the population aged 75-79 had diabetes. When it comes to gender, cases of diabetes were higher among men than women. Research also noted that in middle-income countries there was highest prevalence (11.46 %), followed by high-income (10.21%) and low-income countries (7.47%).

Team of researchers have concluded that since the turn of the millennium, the diabetes epidemic has gone unchecked and more efforts have to be put in to slow down the progression.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store – https://apps.apple.com/in/app/newspin/id6746449540

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post India Ranks Second in Global Diabetes Burden; Pakistan May Overtake US by 2050 appeared first on The CSR Journal.

क्या हैं माइक्रोप्लास्टिक और क्यों हैं खतरनाक?

माइक्रोप्लास्टिक बेहद छोटे प्लास्टिक कण होते हैं, जिनका आकार 5 मिलीमीटर से भी कम होता है। ये प्लास्टिक बोतलों, पैकेजिंग, सिंथेटिक कपड़ों, टायरों और औद्योगिक कचरे के टूटने से बनते हैं। आज ये कण पानी, भोजन और हवा के जरिए हमारे शरीर में प्रवेश कर रहे हैं। कई अध्ययनों में यह पहले ही साबित हो चुका है कि माइक्रोप्लास्टिक इंसानों के रक्त, फेफड़ों और यहां तक कि रिप्रोडक्टिव सिस्टम तक पहुंच चुके हैं।

पिता के संपर्क का बच्चों पर असर: पहली बार सामने आया सबूत

दिसंबर 2025 में यूनिवर्सिटी ऑफ कैलिफोर्निया, रिवरसाइड (यूसी रिवरसाइड) के वैज्ञानिकों द्वारा किया गया यह अध्ययन ‘जर्नल ऑफ द एंडोक्राइन सोसाइटी’ में प्रकाशित हुआ है। यह अपनी तरह का पहला अध्ययन है, जो सीधे तौर पर पिता के माइक्रोप्लास्टिक संपर्क और उनकी संतानों की लंबी अवधि की सेहत के बीच संबंध को दिखाता है। स्टडी के लीड ऑथर और यूसी रिवरसाइड स्कूल ऑफ मेडिसिन में बायोमेडिकल साइंसेज के प्रोफेसर चांगचेंग झोउ के अनुसार, यह रिसर्च पर्यावरणीय स्वास्थ्य के क्षेत्र में एक नया दृष्टिकोण पेश करती है।

स्टडी कैसे की गई?

इस अध्ययन के लिए वैज्ञानिकों ने चूहों को मॉडल के रूप में चुना। नर चूहों को माइक्रोप्लास्टिक के संपर्क में रखा गया और साथ ही उन्हें हाई-फैट डाइट दी गई, ताकि मेटाबॉलिक डिसऑर्डर जैसे हाई ब्लड शुगर, बढ़ा हुआ ब्लड प्रेशर और शरीर में ज्यादा फैट की स्थिति पैदा की जा सके। इसके बाद, इन नर चूहों की संतानों पर माइक्रोप्लास्टिक संपर्क के प्रभावों का अध्ययन किया गया, जबकि सभी संतानों को एक जैसी डाइट दी गई।

बेटियों पर क्यों पड़ा ज्यादा असर?

स्टडी के नतीजे चौंकाने वाले रहे। जिन चूहों के पिता माइक्रोप्लास्टिक के संपर्क में थे, उनकी मादा संतानों में इंसुलिन रेसिस्टेंस विकसित हो गया, जो डायबिटीज का शुरुआती संकेत माना जाता है। इंसुलिन इंजेक्शन के बाद भी उनका ब्लड शुगर जल्दी सामान्य स्तर पर नहीं आया। इसके अलावा, उनकी लिवर में सूजन बढ़ी, डायबिटीज से जुड़े जीन ज्यादा सक्रिय हो गए और मांसपेशियों की ताकत में कमी देखी गई।

इसके उलट, नर संतानों में डायबिटीज जैसे स्पष्ट लक्षणA नहीं पाए गए। हालांकि, उनके शरीर में फैट मास में थोड़ी कमी जरूर देखी गई। कुल मिलाकर, माइक्रोप्लास्टिक का नकारात्मक असर लड़कों की तुलना में लड़कियों पर ज्यादा गंभीर साबित हुआ।

लिंग-विशिष्ट असर अब भी एक रहस्य

वैज्ञानिकों का कहना है कि यह लिंग-विशिष्ट प्रभाव क्यों होता है, इसके पीछे के कारण अभी पूरी तरह स्पष्ट नहीं हैं। प्रोफेसर झोउ के मुताबिक, स्टडी से यह साफ होता है कि प्लास्टिक प्रदूषण का असर सिर्फ उस व्यक्ति तक सीमित नहीं रहता जो इसके संपर्क में है, बल्कि यह एक तरह की जैविक छाप छोड़ सकता है, जो अगली पीढ़ी को पुरानी बीमारियों की ओर धकेल देती है।

भविष्य के पिता के लिए चेतावनी

इस रिसर्च के आधार पर वैज्ञानिकों ने खासतौर पर उन पुरुषों को सावधान रहने की सलाह दी है, जो भविष्य में पिता बनने की योजना बना रहे हैं। उनका कहना है कि माइक्रोप्लास्टिक जैसी हानिकारक चीजों के संपर्क को जितना संभव हो कम किया जाए, ताकि न सिर्फ अपनी सेहत बल्कि आने वाली पीढ़ी की सेहत की भी रक्षा की जा सके।

पर्यावरण की अनदेखी पड़ सकती है भारी

यह अध्ययन एक बार फिर इस बात को रेखांकित करता है कि पर्यावरणीय प्रदूषण सिर्फ आज की समस्या नहीं है, बल्कि इसके असर आने वाली पीढ़ियों तक जा सकते हैं। माइक्रोप्लास्टिक जैसे अदृश्य खतरे भविष्य में डायबिटीज और अन्य मेटाबॉलिक बीमारियों का कारण बन सकते हैं। ऐसे में यह जरूरी हो जाता है कि व्यक्तिगत स्तर से लेकर नीतिगत स्तर तक प्लास्टिक प्रदूषण को गंभीरता से लिया जाए, ताकि आने वाली पीढ़ियों को एक स्वस्थ भविष्य दिया जा सके।

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates

App Store – https://apps.apple.com/in/app/newspin/id6746449540

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post चौंकाने वाला खुलासा: पिता के माइक्रोप्लास्टिक संपर्क से बेटियों में बढ़ सकता है डायबिटीज का खतरा appeared first on The CSR Journal.

India has more young people living with type 1 diabetes (T1D) than anywhere in the world, and the second highest number of people living with diabetes overall[1]. Yet awareness remains low and stigma persist.
The Beyond Type highlights incredible everyday people who are thriving with type 1 diabetes and following their dreams. They are the unstoppable type, the determined type, the relentless type, the inspiring type – they show that type 1 diabetes does not define you.

“India has extraordinary people living with Type 1 diabetes, yet their stories are rarely heard,” shared Priyanka Chopra Jonas. “I came to understand this community more deeply through my husband Nick, and I’ve witnessed firsthand the strength and determination that so many people living with T1D carry every single day. The Beyond Type brings a few of these stories forward, and shows that with proper care and access, diabetes does not define them or limit what they can achieve.”

“I know for myself how diabetes doesn’t have to limit you, but only when you have access to the right care, tools, and support,” says Nick Jonas. “That’s why we’re here in India, where awareness is low and stigma remains high, to help make that possible for everyone. Through my own family, I’ve come to love India deeply, and I’m proud of the progress already underway”.

#TheBeyondType launched on Instagram in a joint post from Priyanka Chopra Jonas, Nick Jonas and Beyond Type 1 who collectively have a combined reach of 135 million. The campaign captures individuals whose stories show that diabetes does not stop them from doing what they want to do: a triathlete Lt Col Kumar Gaurav; 13-year-old karate champion Mehrin Rana; pastry chef Nishant Amin; toy designer and entrepreneur Shreya Jain; dancer and actor Indu Thampy; and vegetable vendor and marathon runner Harichandran Ponnusamy. As Mehrin shares, “Diabetes is just a part of my life, not a limit. A person with type 1 can do everything in their life without any limits.”

Type 1 diabetes is an autoimmune condition, not something caused by lifestyle or age. Yet stigma keeps many families from recognising the early signs — excessive thirst, frequent urination, unusual fatigue and unexpected weight loss. When these signals are missed, diagnosis is delayed. By sharing real-life inspiring stories through #TheBeyondType, the campaign begins to break stigma and open the door to earlier awareness and understanding.

A recent study published in PLOS Global Public Health, Invisible Inequities in Type 1 Diabetes Care in India[2], reinforces the urgency of this work. Conducted in Karnataka with a small group, it found that many young people with T1D hide their diagnosis, some avoid or delay insulin injections in public to escape judgement, and families, especially girls, are pressured to stay silent due to marriage concerns. Healthcare providers reported that young people with T1D are frequently viewed as weak or treated differently in school and at work, showing how stigma shapes daily life and access to care.

The same commitment to lived experience that anchors #TheBeyondType also drives Beyond Type 1’s support for grassroots organisations working across high-need regions in India:

HRIDAY (Delhi–NCR): A youth-driven public health organisation strengthening school and community awareness about early signs and prevention.

Nityaasha Foundation (Pune, Maharashtra): Supporting children from underserved backgrounds living with T1D through education, guidance and medical assistance.

Gram Jyoti (Deoghar, Jharkhand): Bringing early health awareness into classrooms to help families better understand chronic conditions.

SAMATVAM Trust (Bangalore, Karnataka): Empowering girls with T1D through medical care, financial support and life skills training, helping them stay in school and build independent futures.

“At Beyond Type 1 we believe real change begins with the people closest to the work on the ground,” said Seema Srivastava, Beyond Type 1’s Director of Social Impact and Global Advocacy. “By partnering with grassroots organisations, we are helping families recognise early signs, reduce shame and misinformation, and access education, supplies and peer support.”

Disclaimer: This media release is auto-generated. The CSR Journal is not responsible for the content.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store – https://apps.apple.com/in/app/newspin/id6746449540

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post Nick Jonas And Priyanka Chopra Jonas Launch Beyond Type 1’s First Campaign In India appeared first on The CSR Journal.

The Neuberg study, covering a period of two years and released in November 2025, identified regional disparities with the highest rates of diabetes detected in South, West, and Central India, where incidence nears 43 per cent, nearly twice as high as that in Northern regions. Experts believe this rise is fuelled by fast-paced urban lifestyles characterised by sedentary jobs, consumption of processed foods, chronic stress, and irregular sleep patterns. Young urban professionals, students, and early-career adults are increasingly becoming victims of early-onset diabetes, a condition that was once considered unusual in this age group.

Urbanisation and Lifestyle Changes Drive Early Onset Diabetes

India now carries one of the largest burdens of diabetes worldwide, with over 101 million diagnosed cases and 136 million individuals in the prediabetic phase according to the Indian Council of Medical Research’s 2023 data. What is particularly worrying is the trend towards Type 2 diabetes affecting individuals in their twenties and thirties. Early diagnosis means many will live with the disease for decades, significantly increasing risks of serious complications such as heart disease, kidney failure, nerve damage, and vision loss much earlier in life.

Medical experts from Max Healthcare and leading diagnostic centres report a surge in abnormal blood glucose levels among young adults. In 2025, Mahajan Imaging and Labs revealed that a large proportion of adults below 40 tested showed irregularities in fasting glucose, HbA1c, and post-meal glucose results. These alarming figures demonstrate that even youngsters who appear healthy could be harbouring early signs of insulin resistance and metabolic disruption. Experts recommend yearly screenings for all adults after the age of 25 to help detect diabetes early and take preventive or therapeutic action promptly.

Genetic Predisposition Heightens Diabetes Risk in South Asians

The increase in diabetes incidence among young Indians is not merely due to lifestyle factors; genetics also plays a pivotal role. South Asians have a greater genetic predisposition to developing diabetes even at lower body weights compared to Western populations. Studies published in reputed journals show that individuals with high genetic risk linked to insulin production deficiency and abnormal fat distribution develop Type 2 diabetes years earlier and often with lower body mass indexes.

This genetic vulnerability, combined with modern-day environmental challenges like pollution, availability of ultra-processed food delivered at one’s doorstep, long working hours, and disrupted sleep, creates a perfect storm for early metabolic disorders. Insulin resistance is even being detected in children, raising concerns about future health burdens. While India’s expanding network of District and Community Health Centre NCD (Non-Communicable Disease) Clinics strengthens screening capacity, experts stress that mere detection is insufficient. They advocate for a societal and cultural shift where healthy lifestyles, including increased physical activity, wholesome diets, avoidance of sugary drinks, and improving sleep hygiene, become integrated habits to prevent this growing epidemic.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post 18% of Young Adults in India Already Diabetic: Study appeared first on The CSR Journal.

Nafithromycin is a new ketolide antibiotic primarily used to treat drug-resistant respiratory infections, most notably community-acquired bacterial pneumonia (CABP). Its benefits stem from its enhanced efficacy against resistant bacteria, a shorter treatment regimen, and a favorable safety profile compared to older antibiotics.

The antibiotic Nafithromycin has been developed by the Govt of India’s Department of Biotechnology in collaboration with well-known private pharma house Wockhardt. Nafithromycin marks a significant milestone in India’s journey toward innovation-driven healthcare solutions, setting a benchmark in combating antimicrobial resistance.

Key Features of Nafithromycin

Short Treatment Duration: A three-day regimen offering 10 times the efficacy of existing antibiotics.

Broad-Spectrum Action: Targets both typical and atypical pathogens, addressing limitations of antibiotics like azithromycin.

Improved Safety Profile: Minimal gastrointestinal side effects, no significant drug interactions, and unaffected by food consumption.

Global First in 30 Years: Nafithromycin is the first new antibiotic in its class globally in over three decades.

Nafithromycin benefits

Nafithromycin is designed to overcome common resistance mechanisms that impact older macrolides, like azithromycin. It is reported to be up to 10 times more effective than azithromycin against resistant bacterial strains. The drug is potent against a broad spectrum of pathogens that cause respiratory infections, including both typical (e.g., Streptococcus pneumoniae) and atypical (e.g., Mycoplasma pneumoniae and Chlamydia pneumoniae) bacteria. It is particularly effective against multi-drug-resistant (MDR) strains.

Clinical trials have shown that a 3-day course of once-daily oral nafithromycin is as effective as a 7-day course of moxifloxacin for treating CABP. This shorter regimen improves patient compliance and reduces the overall use of antibiotics. The antibiotic achieves high and sustained concentrations in lung tissues, reaching levels eight times higher than azithromycin. This makes it exceptionally effective for treating lung infections like pneumonia.

Nafithromycin is generally well-tolerated with a low risk of significant side effects or drug-drug interactions compared to some other antibiotics, like fluoroquinolones. This makes it a safer option for vulnerable patients, such as the elderly. The antibiotic has anti-inflammatory properties in addition to its antibacterial effects. This immunomodulatory activity may provide additional benefits by resolving secondary complications associated with severe pneumonia.

Ongoing research is exploring Nafithromycin’s potential use against other infections, including skin and soft tissue infections, and its possible role in treating lung cancer due to its interactions with cancer-related proteins.

India must develop self-sustainable ecosystem for scientific & research growth: Dr Jitendra Singh

Citing this as an example of successful industry-academia partnership driving India’s biopharmaceutical growth, the Union Minister emphasised the need to build a self-sustainable innovation ecosystem, so that India could reduce its dependence on government funding and create a culture of private sector participation and philanthropic support to achieve global recognition in research and innovation.

Inaugurating the 3-day Medical Workshop on “Harnessing Artificial Intelligence for Multi-Omics Data Integration and Analysis”, Dr. Jitendra Singh said that India must develop a self-sustainable ecosystem to drive its scientific and research growth. He stated that most nations that have achieved global recognition in science and innovation have done so through self-sustaining, innovation-driven models with extensive engagement of the private sector.

Citing another successful story of government – non government collaboration, the Minister also announced that India has achieved a major breakthrough in gene therapy, marking the first successful indigenous clinical trial for Hemophilia treatment, the trial for which was supported by Govt of India’s Department of Biotechnology and done in a non-government sector hospital, Christian Medical College Vellore.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

The post India launches first indigenous antibiotic Nafithromycin for respiratory infections, benefits cancer patients and diabetics appeared first on The CSR Journal.